Abstract: The outlook for diabetes management has undergone significant evolution, driven by advancements in therapeutic approaches beyond traditional insulin treatments. This article highlights key innovations in diabetes care, including novel insulin formulations (rapid-acting, longacting, and biosimilars), noninsulin therapies, such as GLP-1 receptor agonists, SGLT2 inhibitors, and advanced drug delivery systems encompassing nanoparticle-based technologies, microneedle patches, smart insulin pens, and implantable devices that improve adherence, convenience, and efficacy. Promising avenues such as stem cell-derived beta cells, pancreatic islet cell transplants, and gene editing techniques such as CRISPR are also explored for their potential in curative therapy. Despite the transformational promise of these advances, their clinical implementation requires addressing regulatory and ethical hurdles while ensuring long-term safety, thereby facilitating sustainable, individualized, and potentially curable diabetes treatment.
Sharma et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: